Sigilon Therapeutics had claimed that its cell therapy SIG-001 could have advantages over gene therapies for haemophilia A. Now the group is contending with a hold on the project’s phase 1/2 trial after a patient developed inhibitors.
It is unclear whether SIG-001 caused the issue, and the company suggested that the problem might be patient-specific. Still, the development adds to doubts about uptake of cell and gene therapies for haemophilia, just as the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) approaches.
Gene therapy data
That meeting, being held on July 17-21, will feature data on various haemophilia A gene therapies, including the current frontrunner, Biomarin’s valoctocogene roxaparvovec (valrox), and Roche’s SPK-8011, acquired from Spark. There will also be results with a possible wild card, Bayer/Ultragenyx’s BAY 2599023, which is designed to be a more durable option.
Questions about durability have hung over haemophilia A gene therapies since Biomarin reported phase 1/2 data with valrox. ISTH will see five-year results with the 6x1013vg/kg dose, which might make things clearer; at four years the median factor VIII level was 16% of normal.
At the conference there will also be more data from the pivotal Gener8-1 study, for which initial results were released in January. Although mean factor VIII levels were 43% at one year, there were signs that this was beginning to wane over the longer term (Pivotal valrox data give Biomarin déjà vu, January 11, 2021).
Nevertheless, on this measure valrox still looks more impressive than SPK-8011. The ISTH abstract for the latter details a mean FVIII level of around 12% in 11 patients followed for over two years. It is unclear how important this metric is, or whether the FDA will be more focused on a reduction in bleeding.
Another question is how much of a priority SPK-8011 is for Roche. The group has been relatively quiet about the project since finalising its purchase of Spark in December 2019; the acquisition was scrutinised by the FTC amid worries that Roche might squash the development of SPK-8011 to benefit its haemophilia blockbuster, Hemlibra.
A phase 3 study of SPK-8011 is slated to start this year but there is no sign of it yet. A Roche spokesperson told Evaluate Vantage that the project "remains a priority", but declined to say when the pivotal trial might begin.
Questions over durability – which have also hit Pfizer/Sangamo’s giroctocogene fitelparvovec – could make haemophilia A patients wary about gene therapy, particularly as these therapies cannot be redosed, and patients already have other options.
Step forward Bayer, which believes that it has a longer-lasting candidate in BAY 2599023. Initial data on the project from six patients, presented at last year’s Ash meeting, suggested a dose response, although FVIII levels remained relatively low, apart from in one patient.
However, Bayer’s head of rare disease, Francesca Ferrante, previously stressed to Evaluate Vantage that this is was dose-finding study and that any efficacy would be a bonus.
ISTH will feature data on eight patients, including two new patients receiving a 2x1013vg/kg dose of BAY 2599023 plus prophylactic steroids. Bayer also has the option to increase the dose to 4x1013vg/kg.
As for Sigilon, that group might take heart that other studies of haemophilia A therapies have been put on hold and then restarted again relatively quickly: Novo Nordisk’s concizumab and Alnylam/Sanofi’s fitusiran both managed to overcome non-fatal thrombotic events and get pivotal trials going again last year.
It is also worth noting that inhibitors are a common complication of FVIII therapy, a current mainstay of haemophilia A treatment.
Still, Sigilon’s stock sank 25% on Friday and, with a market cap of $218m, the group is trading not far off cash levels. Gaining an edge in a crowded market was always going to be tricky, and things have just got trickier for the company.
This story has been updated to include comments from Roche.
|Selected novel projects in development for haemophilia A|
|Valoctocogene roxaparvovec||Biomarin Pharmaceutical||Factor VIII gene therapy||Gener8-1, initial data reported Jan 2021|
|Giroctocogene fitelparvovec (SB-525)||Pfizer/Sangamo||Factor VIII gene therapy||Affine|
|Efanesoctocog alfa (BIVV001)||Sanofi/Sobi (ex Bioverativ)||Once-weekly factor VIII replacement therapy||Xtend-1; Xtend-Kids|
|Concizumab||Novo Nordisk||Tissue factor pathway inhibitor antibody||Explorer 7; Explorer 8*|
|Marstacimab (PF-06741086)||Pfizer||Tissue factor pathway inhibitor antibody||Basis|
|Fitusiran||Alnylam/Sanofi||Anti-thrombin-targeting RNAi therapeutic||Atlas A/B; Atlas-PPX*|
|SIG-001||Sigilon Therapeutics||Encapsulated allogeneic factor VIII cell therapy||Ph1/2 on hold – pt developed inhibitors|
|SPK-8011 (RG6357)||Roche (ex Spark)||Factor VIII gene therapy||Ph1/2|
|SPK-8016 (RG6358)||Roche (ex Spark)||Factor VIII gene therapy||Ph1/2 in inhibitor pts|
|BAY 2599023/DTX201||Bayer/Ultragenyx (ex Dimension)||Factor VIII gene therapy||Ph1/2|
|ASC-618||ASC Therapeutics||Factor VIII gene therapy||Ph1/2|
|CD68-ET3-LV||Expression Therapeutics||Haematopoietic stem cell transplantation gene therapy||Ph1|
|*Previously paused but restarted; Source: Evaluate Pharma & clinicaltrials.gov.|